Study Group: Thalomid Prescribers for MDS (US)(?)
Council Members in this Study Group: 45
Request a survey with this Study Group
Leading Experts in this Study Group
Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...
Haitham Al-Okk, MDAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center
Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...
Director of the Oupatient Hematology
THE NEW YORK-PRESBYTERIAN HOSPITAL
Michael Flamm, MD, PhD, is the Director of the Outpatient Hematology Clinic at the Columbia Presbyterian campus of the New York Presbyterian Hospital. He has expertise in the treatment of sickle cell anemia and paroxysmal nocturnal hemoglobinuria, and he also treats patients with hematologic malignancies...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
The author argues that transparency in healthcare will be an important step forward for the consumer.
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes. Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Partner
- Director
- Medical Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms